Reader Question: Watch New Guidelines for Chemodenervation

Why This Topic Matters

It helps readers recognize that chemodenervation coding for migraine changed in 2013 and highlights related billing and coverage issues that can affect claim acceptance.

Article Sections

1. Reader question and coding context

   Introduces the user’s question about chemodenervation reporting for migraine and sets up the coding issue being addressed.

2. 2012 reporting approach and payer considerations

   Summarizes the earlier reporting framework for botulinum toxin injections and notes the broader coverage and medical-necessity concerns discussed in the article.

3. New 2013 CPT option and reporting update

   Describes the addition of a new chemodenervation code and explains the general reporting change associated with multi-area migraine treatment.

4. Bilateral reporting note

   Addresses the article’s final note about session frequency and modifier use in relation to the new code.